Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Partnership could happen any day now MEANS Big Upfront payment very soon .
Research By Griffin Sec ..2 Year Old but very Informative !!!
http://www.griffinsecurities.com/pdf/Company_Reports
/Griffin_CLSN_Initiation_Report_30Jul08.pdf
If you do your homework you will clearly see that this stock will rise rapidly as soon as it gets noticed .
300 Million US$ Market Potential for CPI-300 (antidepressant) approval in 4Q 2010 or early 1Q 2011 !!
Market Cap 10 Mio$
Price : 0,32 $
Shares Out : 33 M
Great Pipeline
http://www.intelgenx.com/_assets/images/productpipeline-2010.gif
Q3/Q4, 2010 Respond to FDA CRL letter
•
Q4,2010 File ANDA antihypertensive product
•
Q1, 2011 Approval of CPI-300 NDA
RALLYYYY WILL CONTINUE TODAY ..PHASE 3 RESULTS COMING IN A FEW DAYS ..DONT MISS IT !!
Two New Presentations within 2 Weeks !!!!
Endo Pharmaceuticals at Jefferies & Co. Global SpecPharma & European Healthcare Conference
Wednesday, October 6, 2010 10:30 a.m. UKT
http://phx.corporate-ir.net/phoenix.zhtml?c=123046&p=irol-EventDetails&EventId=3408691
------
AusBiotech2010
19 to 22 October 2010
http://ausbiotech2010.com.au/uploads/Program/Graeme%20McRae.pdf
-----
STILL VERY VERY VERY CHEAP AT THIS LEVEL .SEE YOU AT 10$+ BY YEAR END !
http://ih.advfn.com/p.php?pid=webchart&symbol=TSE:BNC&period=0&size=19&volume=1
RALLYYYY WILL CONTINUE TODAY ..PHASE 3 RESULTS COMING IN A FEW DAYS ..DONT MISS IT !!
Two New Presentations within 2 Weeks !!!!
Endo Pharmaceuticals at Jefferies & Co. Global SpecPharma & European Healthcare Conference
Wednesday, October 6, 2010 10:30 a.m. UKT
http://phx.corporate-ir.net/phoenix.zhtml?c=123046&p=irol-EventDetails&EventId=3408691
------
AusBiotech2010
19 to 22 October 2010
http://ausbiotech2010.com.au/uploads/Program/Graeme%20McRae.pdf
-----
STILL VERY VERY VERY CHEAP AT THIS LEVEL .SEE YOU AT 10$+ BY YEAR END !
http://ih.advfn.com/p.php?pid=webchart&symbol=TSE:BNC&period=0&size=19&volume=1
RALLYYY HAS JUST BEGUN ..STILL TIME TO GET IN CHEAP !
BIG PAYDAY IS COMING VERY SOON FOR BNC SHAREHOLDERS .
BNC will blasts above $2+ ,if we break $1,60
http://www.barchart.com/cheatsheet.php?sym=BNC.TO
................................................................................
SINGS OF UROCIDIN PHASE 3 SUCCESS .PLEASE DO YOUR OWN DD !
Urocidin Phase 3 success will trigger a 50-60 million$ milestone payment to Bioniche .Market cap of 100 million$ is wayyyyyyy Undervalued .
1) Chief Medical Officer exercise his options for ~ 130.000 C$
Sep 20/10 Sep 20/10 Charette, Francois Guy Direct Ownership Common Shares 51 - Exercise of options 50,000 $1.100
Sep 20/10 Sep 16/10 Charette, Francois Guy Direct Ownership Common Shares 51 - Exercise of options 80,000
.900
...........
2) Urocidin (Bladder Cancer) Phase 3 is a small Studie with 105 Patients,only "20% complete response” required for Phase 3 success .
Previous Positive Phase 2 Results Involving 128 Patients :
We have a 70% complete response rate in patients who failed othertherapies, so our Phase II data, which is in the public domain, shows about 128 patients with an average complete response of about 70%.
..........
3) Complete all DMC ( Data Monitoring Committees) Meetings POSITIV :
Since commencement, nine meetings of the independent DMC have recommended to “continue the trial unmodified”
The DMC is an independent group that acts in an advisory capacity to the Company.Its role is to evaluate the progress of the clinical trial,including monitoring the safety and efficacy data generated in the trial.
..........
4) 21 New Employees since Feb 2010 up from 190 to 211 Personnel :
September 10,
The fully-integrated company employs 211 skilled personnel and has three operating divisions: Human Health, Animal Health, and Food Safety
10/02/10
The fully-integrated company employs approximately 190 skilled personnel and has three operating divisions: Human Health, Animal Health, and Food Safety.
..........
5) Positive Comments by CEO , BladderCancer Forum and Alvaro Morales ( Father of BCG )
CEO Graeme McRae
http://www.quintenews.com/2010/09/banner-year-for-bellevilles-bioniche/
Shareholders will be really happy in two to three years when production of the bladder cancer drug starts to roll onto the market.
BladderCancer Forum (4 months ago)
http://www.bladdercancersupport.org/index.php?option=com_kunena&Itemid=114&func=view&catid=8&id=31827&limit=6&limitstart=12#31862
I can tell you that the people I know at Bioniche are extremely positive about their product.
Alvaro Morales
http://community.advanceweb.com/blogs/al_1/archive/2009/07/13/an-immunotherapy-success-story-bcg-and-bladder-cancer.aspx
Dr Morales, professor of urology and oncologyat Queen’s University, Kingston, Ont., and principal investigator ofthe trial: “My own experience suggests very strongly that the safety profile of MCC is much better than BCG and,certainly, MCC is easier to handle, from the pharmacist’s,nurse’s and physician’s points of view,due to the risk of acquiring a serious infection fromimproper handling of BCG,which is a live bacteria,as opposed to MCC that contains only bacterial cell wall fragments and DNA.”Dr. Morales is editorof The Chronicle of Urology &Sexual Medicine.
........
6) Early (5 months) Exercise of option to take the World Wide Rights for Urocidin by Endo Pharma !
http://www.biospace.com/news_story.aspx?NewsEntityId=170692
Bioniche Life Sciences Inc. (BNC) Achieves Two Additional Milestones Under Licensing Agreement; Endo Pharmaceuticals (ENDP) Takes up Global Rights; Bioniche to Get $8 Million
2/12/2010
-----------------------------------------------------------------------------------------------------------------------------------------------------------
More Information about Bioniche :
http://www.stockhouse.com/Bullboards/MessageDetail.aspx?s=BNC&t=LIST&m=28632016&l=0&pd=0&r=0
Signs of big Phase3 Success
BIG PAYDAY IS COMING FOR BNC SHAREHOLDERS .I LOVE IT .
MAKRET CAP OF 100 MILLION$ IS WAYYYYY UNDERVALUED .
1) Chief Medical Officer exercise his options for ~ 130.000 C$
Sep 20/10 Sep 20/10 Charette, Francois Guy Direct Ownership Common Shares 51 - Exercise of options 50,000 $1.100
Sep 20/10 Sep 16/10 Charette, Francois Guy Direct Ownership Common Shares 51 - Exercise of options 80,000
.900
...........
2) Urocidin (Bladder Cancer) Phase 3 is a small Studie with 105 Patients,only "20% complete response” required for Phase 3 success .
Previous Positive Phase 2 Results Involving 128 Patients :
We have a 70% complete response rate in patients who failed othertherapies, so our Phase II data, which is in the public domain, showsabout 128 patients with an average complete response of about 70%.
..........
3) Complete all DMC ( Data Monitoring Committees) Meetings POSITIV :
Since commencement, nine meetings of the independent DMC have recommended to “continue the trial unmodified”
The DMCis an independent group that acts in an advisory capacity to the Company.Its role is to evaluate the progress of the clinical trial,includingmonitoring the safety and efficacy data generated in thetrial.
..........
4) 21 New Employees since Feb 2010 up from 190 to 211 Personnel :
September 10,
The fully-integrated company employs 211 skilled personnel and has three operating divisions: Human Health, Animal Health, and Food Safety
10/02/10
The fully-integrated company employs approximately 190 skilled personnel and has three operating divisions: Human Health, Animal Health, and Food Safety.
..........
5) Positive Comments by CEO , BladderCancer Forum and Alvaro Morales ( Father of BCG )
CEO Graeme McRae
http://www.quintenews.com/2010/09/banner-year-for-bellevilles-bioniche/
Shareholders will be really happy in two to three years when productionof the bladder cancer drug starts to roll onto the market.
BladderCancer Forum (4 months ago)
http://www.bladdercancersupport.org/index.php?option=com_kunena&Itemid=114&func=view&catid=8&id=31827&limit=6&limitstart=12#31862
I can tell you that the people I know at Bioniche are extremely positive about their product.
Alvaro Morales
http://community.advanceweb.com/blogs/al_1/archive/2009/07/13/an-immunotherapy-success-story-bcg-and-bladder-cancer.aspx
Dr Morales, professor of urology and oncologyat Queen’s University, Kingston, Ont., and principal investigator ofthe trial: “My own experience suggests very stronglythat the safety profile of MCC is much better than BCG and,certainly, MCC iseasier to handle, from the pharmacist’s,nurse’s and physician’s points ofview,due to the risk of acquiring a serious infection fromimproper handling o fBCG,which is a live bacteria,as opposed to MCC thatcontains only bacterial cell wall fragments and DNA.”Dr. Morales is editorof The Chronicle of Urology &Sexual Medicine.
........
6) Early (5 months) Exercise of option to take the World Wide Rights for Urocidin by Endo Pharma !
http://www.biospace.com/news_story.aspx?NewsEntityId=170692
Bioniche Life Sciences Inc. (BNC) Achieves Two Additional Milestones Under Licensing Agreement; Endo Pharmaceuticals (ENDP) Takes up Global Rights; Bioniche to Get $8 Million
2/12/2010
-----------------------------------------------------------------------------------------------------------------------------------------------------------
More Information about Bioniche :
http://www.stockhouse.com/Bullboards/MessageDetail.aspx?s=BNC&t=LIST&m=28632016&l=0&pd=0&r=0
Signs of big Phase3 Success
BIG PAYDAY IS COMING FOR BNC SHAREHOLDERS .I LOVE IT .
MAKRET CAP OF 100 MILLION$ IS WAYYYYY UNDERVALUED .
1) Chief Medical Officer exercise his options for ~ 130.000 C$
Sep 20/10 Sep 20/10 Charette, Francois Guy Direct Ownership Common Shares 51 - Exercise of options 50,000 $1.100
Sep 20/10 Sep 16/10 Charette, Francois Guy Direct Ownership Common Shares 51 - Exercise of options 80,000
.900
...........
2) Urocidin (Bladder Cancer) Phase 3 is a small Studie with 105 Patients,only "20% complete response” required for Phase 3 success .
Previous Positive Phase 2 Results Involving 128 Patients :
We have a 70% complete response rate in patients who failed othertherapies, so our Phase II data, which is in the public domain, showsabout 128 patients with an average complete response of about 70%.
..........
3) Complete all DMC ( Data Monitoring Committees) Meetings POSITIV :
Since commencement, nine meetings of the independent DMC have recommended to “continue the trial unmodified”
The DMCis an independent group that acts in an advisory capacity to the Company.Its role is to evaluate the progress of the clinical trial,includingmonitoring the safety and efficacy data generated in thetrial.
..........
4) 21 New Employees since Feb 2010 up from 190 to 211 Personnel :
September 10,
The fully-integrated company employs 211 skilled personnel and has three operating divisions: Human Health, Animal Health, and Food Safety
10/02/10
The fully-integrated company employs approximately 190 skilled personnel and has three operating divisions: Human Health, Animal Health, and Food Safety.
..........
5) Positive Comments by CEO , BladderCancer Forum and Alvaro Morales ( Father of BCG )
CEO Graeme McRae
http://www.quintenews.com/2010/09/banner-year-for-bellevilles-bioniche/
Shareholders will be really happy in two to three years when productionof the bladder cancer drug starts to roll onto the market.
BladderCancer Forum (4 months ago)
http://www.bladdercancersupport.org/index.php?option=com_kunena&Itemid=114&func=view&catid=8&id=31827&limit=6&limitstart=12#31862
I can tell you that the people I know at Bioniche are extremely positive about their product.
Alvaro Morales
http://community.advanceweb.com/blogs/al_1/archive/2009/07/13/an-immunotherapy-success-story-bcg-and-bladder-cancer.aspx
Dr Morales, professor of urology and oncologyat Queen’s University, Kingston, Ont., and principal investigator ofthe trial: “My own experience suggests very stronglythat the safety profile of MCC is much better than BCG and,certainly, MCC iseasier to handle, from the pharmacist’s,nurse’s and physician’s points ofview,due to the risk of acquiring a serious infection fromimproper handling o fBCG,which is a live bacteria,as opposed to MCC thatcontains only bacterial cell wall fragments and DNA.”Dr. Morales is editorof The Chronicle of Urology &Sexual Medicine.
........
6) Early (5 months) Exercise of option to take the World Wide Rights for Urocidin by Endo Pharma !
http://www.biospace.com/news_story.aspx?NewsEntityId=170692
Bioniche Life Sciences Inc. (BNC) Achieves Two Additional Milestones Under Licensing Agreement; Endo Pharmaceuticals (ENDP) Takes up Global Rights; Bioniche to Get $8 Million
2/12/2010
-----------------------------------------------------------------------------------------------------------------------------------------------------------
More Information about Bioniche :
http://www.stockhouse.com/Bullboards/MessageDetail.aspx?s=BNC&t=LIST&m=28632016&l=0&pd=0&r=0
UPDATE
The technology is great and I believe game changing . I think you will be suitably impressed .ALWAYS DO YOUR OWN DD !!!!
Thermodox Phase III results coming .Thermodox has BLOCKBUSTER POTENTIAL (1-1,5 Billion Dollar Market Potential )
Celsion (CLSN)
Market Cap : 37,4 Mil$
Cash : 5,68 Mil$ (+Celsion Corporation Secures $15 Million)
Price : 3,05 $
Shares Out : 12,27 M
From R&R Presentation:: WATCH
THERMODOX TIMELINE
http://www.wsw.com/webcast/rrshq18/clsn/2__Slide5.JPG
MARKET POTENTIAL
http://www.wsw.com/webcast/rrshq18/clsn/2__Slide7.JPG
Commercialization Plans
http://www.wsw.com/webcast/rrshq18/clsn/2__Slide8.JPG
THERMODOX
http://www.wsw.com/webcast/rrshq18/clsn/2__Slide12.JPG
UPCOMING MILESTONES
http://www.wsw.com/webcast/rrshq18/clsn/2__Slide22.JPG
"We continue to make substantial progress recruiting patients into our Phase III HEAT trial for ThermoDox(R). We continue to track well against our goal to complete enrollment by the end of this year," said Michael Tardugno, President and CEO of Celsion. "We have exceeded our goal of opening enrollment at 70 clinical trial sites with 74 enrolling world-wide. The Phase I/II DIGNITY trial of ThermoDox(R) in patients with recurrent chest wall breast cancer (RCW) also continues to advance. We are currently enrolling patients in the 50mg/m2 dosing cohort, which will be used to determine our therapeutic dose."
This is a real unknown gem ..
The technology is great and I believe game changing.I think you will be suitably impressed .Always do your own DD .
Medifocus (MFS.V) or (MDFZF.PK) Canadian Stock
Market-Cap: 3,6 Mil$
Cash: 3 Mil$
Price: 0,14 $
Shares Out : 26,1 Mio...(CEO holds 5 Mil Shares)
Medifocus, Inc. Announces That It Has Received Approval to Initiate Its Pivotal Phase III Clinical Trial for Treatment of Breast Cancer from the Food and Drug Administration (FDA), Investigational Device Exemption (IDE) Application
http://www.medifocusinc.com/show_company_news.php?nid=129359
Medifocus, Inc. Announces Acceptance at Two Medical Society Meetings: Posters and Oral Presentations on Past Clinical Trial Results and the Upcoming Phase III Pivotal Study will be Given
http://www.medifocusinc.com/show_company_news.php?nid=129539
Fact Sheet
http://www.medifocusinc.com/files/medifocus_fs_Oct2009.pdf
Homepage
http://www.medifocusinc.com/
Market Potential
It is projected that invasive breast cancer cases in the US will have increased to 213,000 new cases in 2006 (National Cancer Institute). This is expected to increase to 480,000 new cases a year by 2017. This market is growing dramatically as the North American population ages.
Management believes that Medifocus’ technology can be useful in the treatment of the entire range of breast cancers. The first indication, large breast cancers, represents 20% of the total incidence of breast cancer. Medifocus is initially targeting 20% of that market.
The Medifocus system will be the first-to-market with its APA solution in 2010 - 2011, when experts suggest that the rate of diagnosis of large breast tumors will reach 76,000.
Bioniche Life Sciences - Gearing Up For D-Day
9/17/2010 7:01 AM ET
http://uk.quote.com/news/story.action?id=RTT009170701000264
carl.pechstein aka scumface ,He is an excellent contraindicator as I have said all along.
THIS HOMO PECHSTEIN BASHES BSDM AT $1 .One week later the stock explodes to 3,50$
http://messages.finance.yahoo.com/Business_%26_Finance/Investments/Stocks_%28A_to_Z%29/Stocks_B/threadview?bn=79227&tid=16194&mid=16198
look what happen 8 days later ..bawahahaha
http://finance.yahoo.com/q/hp?s=BSDM+Historical+Prices
The same story with IPCI .Bought at 1,60$ and sold at 3,20$ .This loser bashes Ipci stock at 1,40$ with his another alias magic_dog2001 one week before the stock explodes to 5$+ .Bawahahaha what a facking Bastard
look at date 2 March 2010
http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_I/threadview?m=tm&bn=100164&tid=402&mid=402&tof=1099&frt=2
look what happen one week later
http://finance.yahoo.com/q/hp?s=IPCI&a=00&b=1&c=2010&d=02&e=19&f=2010&g=d
THIS IS A FANTASTIC SIGN FOR BIONICHE ..
This SICK BASTARD post under many multiple aliases to create the illusion that there are many people who hate a stock and a company.
http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_B/threadview?m=tm&bn=83477&tid=512&mid=512&tof=5&frt=2
Here is the updated aliases list:
bingabro
dovetai1sthomas
carl.pechstein a
profit.zero
magic_dog2001
vasreallysux
thegovernor_elect
equity_addict
notpeterlynch
pumpy_pumpster
LAST CHANCE TO GET IN CHEAP
BNC HITS NEW 2 YEAR-HIGH TODAY = MAJOR BREAKOUT COMING
http://www.barchart.com/chart.php?sym=BNC.TO&style=technical&p=DO&d=O&sd=&ed=&size=M&log=0&t=CANDLE&v=1&g=1&evnt=1&late=1&o1=&o2=&o3=&x=28&y=9&sh=100&indicators=SMA%28200%2C16711680%29&chartindicator_2_code=SMA&chartindicator_2_param_0=200&chartindicator_2_param_1=16711680&addindicator=&submitted=1&fpage=&txtDate=#jump
Market cap of 90 M$ is wayyyyyyy undervalued .
Urocidin (Bladder Cancer) Phase 3 results in September (VERY LOW RISK ) . Only 105 Patients in current Phase 3 .Check out the POSITIVE Phase2 results from 2008 involving 128 Patients (see post below) !!!!
TWST: Give us more detail on that pipeline. What is near term and what is a little longer term?
Mr. McRae: The primary technology is called Mycobacterial Cell Wall-DNA Complex, and it sounds like a mouthful but really we found a naturally occurring bacteria where the DNA of the bacteria had a very unusual property ' it can actually kill cancer cells. It kills cancer cells in the face of mutations that would normally stop chemotherapy or radiation therapy from being effective. [B]This DNA is quite unique in that the tumor cells, even when they try to mutate around it, are unable to induce resistance to this compound; and it's extremely safe. We have a 70% complete response rate in patients who failed other therapies, so our Phase II data, which is in the public domain, shows about 128 patients with an average complete response of about 70%. These are patients who at the end of the study were disease-free and had really no side effects worth noting due to the product.[/B] The patients were able to maintain treatment, whereas without the treatments they drop out because of side effects, so that is our primary technology. It has been shown effective in-vitro in the lab against many different types of cancer. In fact, we can't find a cancer cell it doesn't kill. But in our clinical plan, it is bladder cancer first and prostate cancer second. In prostate cancer, we have completed a Phase I study
LAST CHANCE TO GET IN CHEAP !
BNC HITS NEW 2 YEAR-HIGH TODAY = MAJOR BREAKOUT COMING
http://www.barchart.com/chart.php?sym=BNC.TO&style=technical&p=DO&d=O&sd=&ed=&size=M&log=0&t=CANDLE&v=1&g=1&evnt=1&late=1&o1=&o2=&o3=&x=28&y=9&sh=100&indicators=SMA%28200%2C16711680%29&chartindicator_2_code=SMA&chartindicator_2_param_0=200&chartindicator_2_param_1=16711680&addindicator=&submitted=1&fpage=&txtDate=#jump
Market cap of 90 M$ is wayyyyyyy undervalued .
Urocidin (Bladder Cancer) Phase 3 results in September (VERY LOW RISK ) . Only 105 Patients in current Phase 3 .Check out the POSITIVE Phase2 results from 2008 involving 128 Patients (see post below) !!!!
TWST: Give us more detail on that pipeline. What is near term and what is a little longer term?
Mr. McRae: The primary technology is called Mycobacterial Cell Wall-DNA Complex, and it sounds like a mouthful but really we found a naturally occurring bacteria where the DNA of the bacteria had a very unusual property ' it can actually kill cancer cells. It kills cancer cells in the face of mutations that would normally stop chemotherapy or radiation therapy from being effective. [B]This DNA is quite unique in that the tumor cells, even when they try to mutate around it, are unable to induce resistance to this compound; and it's extremely safe. We have a 70% complete response rate in patients who failed other therapies, so our Phase II data, which is in the public domain, shows about 128 patients with an average complete response of about 70%. These are patients who at the end of the study were disease-free and had really no side effects worth noting due to the product.[/B] The patients were able to maintain treatment, whereas without the treatments they drop out because of side effects, so that is our primary technology. It has been shown effective in-vitro in the lab against many different types of cancer. In fact, we can't find a cancer cell it doesn't kill. But in our clinical plan, it is bladder cancer first and prostate cancer second. In prostate cancer, we have completed a Phase I study
LAST CHANCE TO GET IN CHEAP -- PLEASE do your own RESEARCH !!!
BNC HITS NEW 2 YEAR-HIGH TODAY = MAJOR BREAKOUT COMING
http://www.barchart.com/chart.php?sym=BNC.TO&style=technical&p=DO&d=O&sd=&ed=&size=M&log=0&t=CANDLE&v=1&g=1&evnt=1&late=1&o1=&o2=&o3=&x=28&y=9&sh=100&indicators=SMA%28200%2C16711680%29&chartindicator_2_code=SMA&chartindicator_2_param_0=200&chartindicator_2_param_1=16711680&addindicator=&submitted=1&fpage=&txtDate=#jump
POSITIVE PHASE 3 RESULTS WILL PUSH THIS STOCK TO $4-6 EASILY .PHASE 3 SUCCESS WILL TRIGGER A 50-60 MIL$+ MILESTONE PAYMENT TO BNC
Urocidin (Bladder Cancer) Phase 3 results in September (VERY LOW RISK ) . Only 105 Patients in current Phase 3 .Check out the POSITIVE Phase2 results from 2008 involving 128 Patients (see post below) !!!!
Bioniche Life Sciences (BNC.TO)
Market Cap: 72 Mil$
Cash: 22 Mil $
Price: 0,99 $
***** BUY RATING BY DUNDEE SEC *****
Bioniche has three businesses with diversified risk/reward profiles:Animal Health, which is expected to generate around $28 million in salesin fiscal 2010; Human Health, with Phase 3 results expected in mid-2010 from lead product, Urocidin, testing for bladder cancer; and FoodSafety, with Canadian approval and a conditional license pending in theU.S. of a vaccine for reducing E. coli 0157 in cattle feces, and apipeline of other vaccines.
Mr. Martin points out that Urocidin provides the “biggest upside potential” for Bioniche investors. His initial diligence suggests that Urocidin has a “relatively high overall probability of approval,” eventhough the first of two planned Phase 3 trials has a moderate level ofrisk, as the refractory patients enrolled in the trial are a“tougher-to-treat” population than was enrolled in the Phase 2 trial, hesays.
Mitigating the risk somewhat is the 20% “complete response” hurdlerequired for Phase 3. That compares with the company’s Phase 2 results,where patients achieved a 46.4% CR rate at 26 weeks in a population thatwas mainly relapsed but also included a few patients being treated forthe first time.
A second planned Phase 3 trial will test Urocidin head-to-head againstthe current standard of care, baccilus Calmette-Guerin (BCG) infirst-line treatment, “where we expect Urocidin to demonstrate betterefficacy, based on prior data, and superior safety and tolerability,” hepredicts.
In 2009, Bioniche licensed Urocidin’s U.S. commercial rights to EndoPharmaceuticals. Based on incidence of bladder cancer and possiblepricing, he figures the global market opportunity for Urocidin in therefractory population could be $800 million. If the second Phase 3 trialexpands the Urocidin label to first-line treatment, the marketopportunity could grow to an estimated $2 billion.
“Twenty-five percent penetration of this market would represent $500million in annual sales and an estimated $112.5 million in gross profitfor Bioniche,” Mr. Martin says .
----------------------------------------
TWST: Give us more detail on that pipeline. What is near term and what is a little longer term?
Mr. McRae: The primary technology is called Mycobacterial Cell Wall-DNA Complex, and it sounds like a mouthful but really we found a naturally occurring bacteria where the DNA of the bacteria had a very unusual property ' it can actually kill cancer cells. It kills cancer cells in the face of mutations that would normally stop chemotherapy or radiation therapy from being effective. This DNA is quite unique in that the tumor cells, even when they try to mutate around it, are unable to induce resistance to this compound; and it's extremely safe. We have a 70% complete response rate in patients who failed other therapies, so our Phase II data, which is in the public domain, shows about 128 patients with an average complete response of about 70%. These are patients who at the end of the study were disease-free and had really no side effects worth noting due to the product. The patients were able to maintain treatment, whereas without the treatments they drop out because of side effects, so that is our primary technology. It has been shown effective in-vitro in the lab against many different types of cancer. In fact, we can't find a cancer cell it doesn't kill. But in our clinical plan, it is bladder cancer first and prostate cancer second. In prostate cancer, we have completed a Phase I study
Breakout coming ....
http://www.barchart.com/cheatsheet.php?sym=CBP
Earnings will push this stock to $3+
LOW FLOAT 4,7 M = Once wall street discovers this stock, it will explode !
http://chinainvestorking.blogspot.com/2010/06/renhuang-pharmaceuticals-rhgp-almost.html
Renhuang Pharma (Amex: CBP )
Market Cap : 60,7 M$
Cash : 24,85 $
Price : 1,60$
Shares Out : 37 M
Low Float : 4,7 M
China Tracker has rated CBP with 20 stars, which is the highest of any listed stock. The average rating is about a 5, with many stocks rated below 0 and some as low as -9.
http://www.fixyou.co.uk/tracker_scorecards.php
Reasons this stock is loved by China Tracker (listed by importance)
1. Excellent earning growth Y/Y (53%).
2. Extremely low PE (past 4 quarters) (3.51)
3. Extremely low forward projected PE (3.92)
4. High projected cash flow (1.97)
5. High Net income growth (62%)
6. Good revenue growth Y/Y (39%)
7. Good price / book (124%)
8. No Debt (0%) <<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<< NO DEBT
9. Declining acct. receivable (-28%)
10. Cash as percentage of share price (31%)
11. Low share delusion (8.4%)
re New Highs coming
NEW 52W HIGH woooohooooo.. MAJOR BREAKOUT COMING
http://ih.advfn.com/p.php?pid=webchart&symbol=TSE:BNC&period=0&size=19&volume=1
NEW 52W HIGH woooohooooo.. MAJOR BREAKOUT COMING
http://ih.advfn.com/p.php?pid=webchart&symbol=TSE:BNC&period=0&size=19&volume=1
re BNC ..NEW 52W HIGH woooohooooo.. MAJOR BREAKOUT COMING
http://ih.advfn.com/p.php?pid=webchart&symbol=TSE:BNC&period=0&size=19&volume=1
Market Cap of 18 Mil4 is wayyy undervalued
Dr. Struby continued, “Our efforts with respect to our 510(k) premarket submission filing with the U.S. Food and Drug Administration for the Mago® 4S, our next-generation fully automated ELISA system for autoimmune and infectious disease testing, are progressing, and we continue to expect to receive regulatory approval from the FDA and launch the product during the fourth quarter of 2010. Following the receipt of all required regulatory approvals and the subsequent commercial launch of the product, we expect the Mago® 4S will provide a flexible, efficient and cost-effective solution to high-performance laboratories, and will be our primary platform for marketing our kits in the U.S.”
Dr. Struby concluded, “While we believe that the initiatives we have implemented are a positive step towards our goal of transforming our company, we know that our work is not complete and that there remain challenges to overcome as we position IVAX Diagnostics for growth. We intend to continue our focus for the remainder of this year on cost control as we prepare for the Mago® 4S launch and its expected impact. We look forward to reporting on our efforts and initiatives in the upcoming months.”
Breakout is coming
Dont miss the train ..Approval will happen any day now
2$ IS COMING !!!!
GOOD NEWS
IVAX Diagnostics Reports Purchase of Majority Stockholders' Interests
Press Release Source: IVAX Diagnostics, Inc. On Wednesday September 1, 2010, 11:06 am
MIAMI--(BUSINESS WIRE)--IVAX Diagnostics, Inc. (NYSE Amex: IVD), a fully integrated in vitro diagnostics company, announced that today ERBA Diagnostics Mannheim GmbH purchased from a group controlled by Patrice Debregeas and Paul Kennedy all of the approximately 72% of the outstanding shares of IVAX Diagnostics owned by their group for $0.75 per share, or an aggregate purchase price of approximately $15 million. ERBA Diagnostics Mannheim, headquartered in Mannheim, Germany, is an emerging player in the in vitro diagnostics market.
APPROVAL IS COMING VERY SOON
IVD IS SIGNIFICANTLY UNDERVALUED...
re BNC.TO <<< RALLY
POSITIVE RESULTS WILL PUSH THIS STOCK TO $6+ EASILY ..GLTA
Only 105 patients in current PhaseIII !!!!
Positive results from 2008 INVOLVING 130 PATIENTS !!!!
In November 2008,
during a meeting of urologists in Santigo Chile, the biopharmaceutical research company presented positive clinical studies (one and two) involving 130 bladder cancer patients treated with Urocidin. Elderly patients (average 73 years old) during the clinical studies noted excellent safety results
------------------------
Bioniche Phase III Clinical Trial With Urocidin(TM) Given Continued Green Light By DMC
The Data Monitoring Committee (DMC) held its ninth meeting regarding this clinical trial last week. After its meeting, the Committee has recommended that Bioniche "continue the trial unmodified until the next scheduled or triggered meeting."
The DMC is an independent group that acts in an advisory capacity to the Company. Its role is to evaluate the progress of the clinical trial, including monitoring the safety and efficacy data generated in the trial.
POSITIVE RESULTS WILL PUSH THIS STOCK TO$6+ EASILY .GLTA
Bioniche life sciences ( BNC.TO )
Only 105 patients in current PhaseIII !!!!
Positive results from 2008 INVOLVING 130 PATIENTS !!!!
In November 2008,
during a meeting of urologists in Santigo Chile, the biopharmaceutical research company presented positive clinical studies (one and two) involving 130 bladder cancer patients treated with Urocidin. Elderly patients (average 73 years old) during the clinical studies noted excellent safety results
------------------------
Bioniche Phase III Clinical Trial With Urocidin(TM) Given Continued Green Light By DMC
The Data Monitoring Committee (DMC) held its ninth meeting regarding this clinical trial last week. After its meeting, the Committee has recommended that Bioniche "continue the trial unmodified until the next scheduled or triggered meeting."
The DMC is an independent group that acts in an advisory capacity to the Company. Its role is to evaluate the progress of the clinical trial, including monitoring the safety and efficacy data generated in the trial.
THE RUNUP HAS JUST..........Next DENDREON HERE !!!
POSITIVE results coming next Month.Don´t miss the BIG OPPORTUNITY
FDA approval for Econiche (E.coli Vaccine) & Urocidin (Bladder Cancer) Phase III results in 3Q 2010 !!
Bioniche Has The Potential To Become The Next 10-Bagger .GOOD LUCK !!!!!!!
Bioniche Life Sciences (TSX: BNC) !!
Market Cap: 72 Mil $
Cash: 22 Mil $
Price: 0,99 $
Dundee Sec with Buy-Rating (June 2010)....
Bioniche has three businesses with diversified risk/reward profiles:Animal Health, which is expected to generate around $28 million in salesin fiscal 2010; Human Health, with Phase 3 results expected in mid-2010from lead product, Urocidin, testing for bladder cancer; and FoodSafety, with Canadian approval and a conditional license pending in theU.S. of a vaccine for reducing E. coli 0157 in cattle feces, and apipeline of other vaccines.
Mr. Martin points out that Urocidin provides the “biggest upsidepotential” for Bioniche investors. His initial diligence suggests thatUrocidin has a “relatively high overall probability of approval,” eventhough the first of two planned Phase 3 trials has a moderate level ofrisk, as the refractory patients enrolled in the trial are a“tougher-to-treat” population than was enrolled in the Phase 2 trial, hesays.
Mitigating the risk somewhat is the 20% “complete response” hurdlerequired for Phase 3. That compares with the company’s Phase 2 results,where patients achieved a 46.4% CR rate at 26 weeks in a population thatwas mainly relapsed but also included a few patients being treated forthe first time.
A second planned Phase 3 trial will test Urocidin head-to-head againstthe current standard of care, baccilus Calmette-Guerin (BCG) infirst-line treatment, “where we expect Urocidin to demonstrate betterefficacy, based on prior data, and superior safety and tolerability,” hepredicts.
In 2009, Bioniche licensed Urocidin’s U.S. commercial rights to EndoPharmaceuticals. Based on incidence of bladder cancer and possiblepricing, he figures the global market opportunity for Urocidin in therefractory population could be $800 million. If the second Phase 3 trialexpands the Urocidin label to first-line treatment, the marketopportunity could grow to an estimated $2 billion.
“Twenty-five percent penetration of this market would represent $500million in annual sales and an estimated $112.5 million in gross profitfor Bioniche,” Mr. Martin says .
BUYOUT IS COMING !!!
http://finance.yahoo.com/news/Endo-Pharmaceuticals-Looks-ibd-4281469438.html?x=0&.v=1
Endo Pharmaceuticals Looks For Acquisitions
On Friday August 27, 2010, 4:40 pm EDT
To broaden its product base, Endo has also done some in-licensing. In July, 2009, Endo acquired exclusive rights from Bioniche Life Sciences to develop and market phase-three drug Urocidin for bladder cancer in the U.S. with a global marketing option.
Having bought Penwest, Endo can now make all the decisions about Opana without consultation.[B] It also won't need to pay Penwest the 22% in royalties[/B] that were part of the previous partnership deal.
re BNC.TO
Buyout is coming !!!!!!!!!!!!!
http://finance.yahoo.com/news/Endo-Pharmaceuticals-Looks-ibd-4281469438.html?x=0&.v=1
Endo Pharmaceuticals Looks For Acquisitions
On Friday August 27, 2010, 4:40 pm EDT
To broaden its product base, Endo has also done some in-licensing. In July, 2009, Endo acquired exclusive rights from Bioniche Life Sciences to develop and market phase-three drug Urocidin for bladder cancer in the U.S. with a global marketing option.
Having bought Penwest, Endo can now make all the decisions about Opana without consultation.[B] It also won't need to pay Penwest the 22% in royalties[/B] that were part of the previous partnership deal.
re THE RUNUP HAS JUST BEGUN !!!!
BREAKOUT COMING
Bioniche & University of Ottawa Sign Exclusive Global License Agreement for Natural Health Technology - Yahoo! Finance
http://finance.yahoo.com/news/Bioniche-University-of-Ottawa-cnw-3715696021.html?x=0
Press Release Source: Bioniche Life Sciences Inc. On Wednesday August 25, 2010, 7:00 am
- potential animal health and human health applications for reduction of anxiety -
re BNC.TO RAALLLYYYY
Good News ...BREAKOUT COMING
Bioniche & University of Ottawa Sign Exclusive Global License Agreement for Natural Health Technology - Yahoo! Finance
Bioniche & University of Ottawa Sign Exclusive Global License Agreement for Natural Health Technology
Press Release Source: Bioniche Life Sciences Inc. On Wednesday August 25, 2010, 7:00 am
- potential animal health and human health applications for reduction of anxiety -
re BNC.TO RALLLYYYYYY
THE RALLLLYYYY HAS JUST BEGUN !!!! get in now before its too late .this stock is a lifetime opportunity .
Bioniche life science (BNC.TO) . Market cap of 80 mil$ is a big joke ..
Positive Phase 3 results coming next month .Urocidin for bladder cancer is a real Blockbuster (1-2 Billion Dollars Potential) .
Positive results will trigger a big milestone payment for Bioniche .
In 2009, Bioniche licensed Urocidin’s U.S. commercial rights to Endo Pharmaceuticals . Based on incidence of bladder cancer and possible pricing, he figures the global market opportunity for Urocidin in the refractory population could be $800 million. If the second Phase 3 trial expands the Urocidin label to first-line treatment, the market opportunity could grow to an estimated $2 billion.
HUGE BREAKOUT IS COMING ...
http://3.bp.blogspot.com/_4f_p2K3hwOo/THHOw07Y25I/AAAAAAAAKBA/jj2FGUf0ybE/s1600/bnc.png" rel="nofollow" target="_blank" >http://3.bp.blogspot.com/_4f_p2K3hwOo/THHOw07Y25I/AAAAAAAAKBA/jj2FGUf0ybE/s1600/bnc.png
http://www.barchart.com/cheatsheet.php?sym=BNC.TO" rel="nofollow" target="_blank" >http://www.barchart.com/cheatsheet.php?sym=BNC.TO
THE RUNUP HAS JUST BEGUN !!!! get in now before its too late .this stock is a lifetime opportunity .
Bioniche life science (BNC.TO) . Market cap of 80 mil$ is a big joke ..
Positive Phase 3 results coming next month .Urocidin for bladder cancer is a real Blockbuster (1-2 Billion Dollars Potential) .
Positive results will trigger a big milestone payment for Bioniche .
In 2009, Bioniche licensed Urocidin’s U.S. commercial rights to Endo Pharmaceuticals . Based on incidence of bladder cancer and possible pricing, he figures the global market opportunity for Urocidin in the refractory population could be $800 million. If the second Phase 3 trial expands the Urocidin label to first-line treatment, the market opportunity could grow to an estimated $2 billion.
HUGE BREAKOUT IS COMING ...
http://3.bp.blogspot.com/_4f_p2K3hwOo/THHOw07Y25I/AAAAAAAAKBA/jj2FGUf0ybE/s1600/bnc.png" rel="nofollow" target="_blank" >http://3.bp.blogspot.com/_4f_p2K3hwOo/THHOw07Y25I/AAAAAAAAKBA/jj2FGUf0ybE/s1600/bnc.png
http://www.barchart.com/cheatsheet.php?sym=BNC.TO" rel="nofollow" target="_blank" >http://www.barchart.com/cheatsheet.php?sym=BNC.TO
US Approval in 3Q/4Q10 = $$$$$$$
This stock is definitely flying under the Radar .GET IN NOW before the stock gets discovered !! GLTA
LOW FLOAT 7,5 M = Once wall street discovers this stock, it will explode !
IVAX Diagnostics (AMEX: IVD)
Market Cap: 15.24M
Price: 0,55 $
Shares Outstanding: 27.65M -- (18 M Shares held by Insiders)
Float: 7.50M
Dr. Struby continued, “Our efforts with respect to our 510(k) premarket submission filing with the U.S. Food and Drug Administration for the Mago® 4S, our next-generation fully automated ELISA system for autoimmune and infectious disease testing, are progressing, and we continue to expect to receive regulatory approval from the FDA and launch the product during the fourth quarter of 2010. Following the receipt of all required regulatory approvals and the subsequent commercial launch of the product, we expect the Mago® 4S will provide a flexible, efficient and cost-effective solution to high-performance laboratories, and will be our primary platform for marketing our kits in the U.S.”
RALLLYYYY HAS JUST BEGUN !!!
Positive results is around the corner..Dont miss the train !!
FDA approval for Econiche (E.coli Vaccine) & Urocidin (Bladder Cancer) Phase III Data in 3Q 2010 !! .Please do your own Homework.
Bioniche Has The Potential To Become The Next 10-Bagger .GLTA !!
Bioniche Life Sciences (TSX:BNC) !!
Market Cap: 74,6 Mil $
Cash: 22 Mil $
Price: 1,03 $
Dundee Sec with Buy-Rating (June 2010)....
Bioniche has three businesses with diversified risk/reward profiles:Animal Health, which is expected to generate around $28 million in salesin fiscal 2010; Human Health, with Phase 3 results expected in mid-2010from lead product, Urocidin, testing for bladder cancer; and FoodSafety, with Canadian approval and a conditional license pending in theU.S. of a vaccine for reducing E. coli 0157 in cattle feces, and apipeline of other vaccines.
Mr. Martin points out that Urocidin provides the “biggest upsidepotential” for Bioniche investors. His initial diligence suggests thatUrocidin has a “relatively high overall probability of approval,” eventhough the first of two planned Phase 3 trials has a moderate level ofrisk, as the refractory patients enrolled in the trial are a“tougher-to-treat” population than was enrolled in the Phase 2 trial, hesays.
Mitigating the risk somewhat is the 20% “complete response” hurdlerequired for Phase 3. That compares with the company’s Phase 2 results,where patients achieved a 46.4% CR rate at 26 weeks in a population thatwas mainly relapsed but also included a few patients being treated forthe first time.
A second planned Phase 3 trial will test Urocidin head-to-head againstthe current standard of care, baccilus Calmette-Guerin (BCG) infirst-line treatment, “where we expect Urocidin to demonstrate betterefficacy, based on prior data, and superior safety and tolerability,” hepredicts.
In 2009, Bioniche licensed Urocidin’s U.S. commercial rights to EndoPharmaceuticals. Based on incidence of bladder cancer and possiblepricing, he figures the global market opportunity for Urocidin in therefractory population could be $800 million. If the second Phase 3 trialexpands the Urocidin label to first-line treatment, the marketopportunity could grow to an estimated $2 billion.
“Twenty-five percent penetration of this market would represent $500million in annual sales and an estimated $112.5 million in gross profitfor Bioniche,” Mr. Martin says .
BNC.TO << RALLLLYYYYYYY
RUNUP STARTED
FDA approval for Econiche (E.coli Vaccine) & Urocidin (Bladder Cancer) Phase III Data in 3Q 2010 !! Bioniche has tremendous upside Potential .Please do your own Homework.
Bioniche Has The Potential To Become The Next 10-Bagger .GLTA !!
Bioniche Life Science (BNC.TO) !!
Market Cap: 74,6 Mio $
Cash: 22 Mio $
Price: 1,03 $
Dundee Sec with Buy-Rating (June 2010)....
Bioniche has three businesses with diversified risk/reward profiles:Animal Health, which is expected to generate around $28 million in salesin fiscal 2010; Human Health, with Phase 3 results expected in mid-2010from lead product, Urocidin, testing for bladder cancer; and FoodSafety, with Canadian approval and a conditional license pending in theU.S. of a vaccine for reducing E. coli 0157 in cattle feces, and apipeline of other vaccines.
Mr. Martin points out that Urocidin provides the “biggest upsidepotential” for Bioniche investors. His initial diligence suggests thatUrocidin has a “relatively high overall probability of approval,” eventhough the first of two planned Phase 3 trials has a moderate level ofrisk, as the refractory patients enrolled in the trial are a“tougher-to-treat” population than was enrolled in the Phase 2 trial, hesays.
Mitigating the risk somewhat is the 20% “complete response” hurdlerequired for Phase 3. That compares with the company’s Phase 2 results,where patients achieved a 46.4% CR rate at 26 weeks in a population thatwas mainly relapsed but also included a few patients being treated forthe first time.
A second planned Phase 3 trial will test Urocidin head-to-head againstthe current standard of care, baccilus Calmette-Guerin (BCG) infirst-line treatment, “where we expect Urocidin to demonstrate betterefficacy, based on prior data, and superior safety and tolerability,” hepredicts.
In 2009, Bioniche licensed Urocidin’s U.S. commercial rights to EndoPharmaceuticals. Based on incidence of bladder cancer and possiblepricing, he figures the global market opportunity for Urocidin in therefractory population could be $800 million. If the second Phase 3 trialexpands the Urocidin label to first-line treatment, the marketopportunity could grow to an estimated $2 billion.
“Twenty-five percent penetration of this market would represent $500million in annual sales and an estimated $112.5 million in gross profitfor Bioniche,” Mr. Martin says
FDA APPROVAL NEWS ...
UP 42% in Pre -Market
http://finance.yahoo.com/news/BSD-Medical-Receives-FDA-510k-bw-613610333.html?x=0&.v=1
BSD Medical Receives FDA 510(k) Clearance to Market the MicroThermX Microwave Ablation System
Press Release Source: BSD Medical Corporation On Wednesday August 18, 2010, 7:00 am EDT
SALT LAKE CITY--(BUSINESS WIRE)--BSD Medical Corporation (NASDAQ:BSDM - News) (Company or BSD) today announced that the U.S. Food and Drug Administration (FDA) has granted the Company a 510(k) clearance to market its MicroThermX Microwave Ablation System (MTX-180) for ablation of soft tissue. Clearance from the FDA of BSD’s 510(k) Premarket Notification submission authorizes the commercial sale of the MTX-180 in the United States. The MTX-180 was designed to provide a higher power, optimized system targeted to the growing therapeutic interventional and surgical oncology market.
UP 42% in Pre -Market
http://finance.yahoo.com/news/BSD-Medical-Receives-FDA-510k-bw-613610333.html?x=0&.v=1
BSD Medical Receives FDA 510(k) Clearance to Market the MicroThermX Microwave Ablation System
Press Release Source: BSD Medical Corporation On Wednesday August 18, 2010, 7:00 am EDT
SALT LAKE CITY--(BUSINESS WIRE)--BSD Medical Corporation (NASDAQ:BSDM - News) (Company or BSD) today announced that the U.S. Food and Drug Administration (FDA) has granted the Company a 510(k) clearance to market its MicroThermX Microwave Ablation System (MTX-180) for ablation of soft tissue. Clearance from the FDA of BSD’s 510(k) Premarket Notification submission authorizes the commercial sale of the MTX-180 in the United States. The MTX-180 was designed to provide a higher power, optimized system targeted to the growing therapeutic interventional and surgical oncology market.